Eli Lilly (LLY) announced a $4.5 billion expansion across two of its Lebanon, Indiana manufacturing sites on May 6, 2026. LLY stock was up 2.16%, trading around $988.87 at the time of the announcement.
The fresh investment brings Lilly’s total Indiana capital commitments since 2020 to over $21 billion. Across the U.S., that number climbs above $50 billion.
The money is split between two Lebanon sites. The first is Lilly Lebanon Advanced Therapies, which officially opened today. The second is Lilly Lebanon API, a future active pharmaceutical ingredient facility set to open in 2027.
Eli Lilly is spending another $4.5 billion on its manufacturing plants in Indiana as the pharmaceutical company shores up its domestic supply chain. https://t.co/0Kpx54TUjD
— Bloomberg (@business) May 6, 2026
The Advanced Therapies facility is Lilly’s first site built specifically for genetic medicine manufacturing. It covers the full range of genetic medicine modalities, from early clinical development through large-scale commercial supply.
Building it wasn’t straightforward. Lilly had to develop new manufacturing processes from scratch, with no established commercial blueprint to follow.
The Lebanon API site has a bigger immediate commercial story. It will produce tirzepatide, the active ingredient in both Zepbound and Mounjaro — currently the most prescribed injectable medications for weight management and type 2 diabetes respectively.
The site will also manufacture Foundayo (orforglipron), Lilly’s recently FDA-approved once-daily weight loss pill. Unlike injectable options, Foundayo can be taken without food or water restrictions.
Retatrutide, an investigational triple hormone receptor agonist in late-stage development for obesity and cardiometabolic disease, is also on the production list.
When the Lebanon API site opens in 2027, Lilly says it will be the largest API production facility in U.S. history.
The Lebanon campus is designed to hold three sites in total. Alongside the Advanced Therapies facility and the API site, a third — the Lilly Medicine Foundry — is also planned.
CEO David Ricks framed the announcement in direct terms. “We are not just discovering the medicines of the future — we are building the world’s most advanced plants to make them,” he said.
Indiana Governor Mike Braun welcomed the investment, pointing to it as evidence of the state’s strength in life sciences and advanced manufacturing.
A forthcoming report from Indiana University’s Kelley School of Business puts some numbers around Lilly’s local impact. According to the report, Lilly accounts for 70% of Indiana’s pharmaceutical GDP. Every Lilly job is estimated to support more than two additional jobs across the state, and every dollar Lilly spends in the area generates up to four dollars in broader local economic activity.
Lilly said it plans to break ground on several of its recently announced U.S. manufacturing sites this year. The Lebanon campus remains the centerpiece of that domestic buildout.
The Lebanon Advanced Therapies site is the first of three planned on the campus, with the API facility and Medicine Foundry to follow.
Lilly’s pipeline expansion — including late-stage candidates like retatrutide — was cited by the company as a key driver behind the additional capital commitment.
The post Eli Lilly (LLY) Stock: Lilly Is Building the Largest Drug Plant in U.S. History appeared first on CoinCentral.
